Cascador Health bridges the gap between data sources and the users of healthcare data.
Melle, 9 October 2024 - Cascador Health strengthens its market position in Europe with the acquisitions of Galenus Health and Neuroventis. Together, they contribute to improving healthcare in three of the fastest-evolving specializations—oncology immunology, and neurology—through insights gained from real-world data (RWD). Following these acquisitions, Cascador now offers in-depth insights into the full lifecycle of medicines, from research & development to market access and commercialisation. This benefits the pharmaceutical industry, the treating physician, and, most importantly, the patient.
Throughout the lifecycle of a medical product, pharmaceutical companies often rely on real-world data —or clinical practice data— to demonstrate the clinical value in large patient populations, to obtain reimbursement approval, to navigate more precisely in markets and to accelerate the adoption of medical products. Today, the sector faces challenges accessing such crucial data due to legal and technical constraints. While Cascador had previously focused on oncology treatment data, the acquisition of Galenus and Neuroventis now provides immediate access to insights into immunology and neurology.
The global pharmaceuticals market in 2023 is estimated at 1071 billion euros (of which oncology represents more than 25%, immunology about 20% and neurology 7%, together more than half of the market) and is expected to grow to 1363 billion euros by 2029. Because these three therapeutic areas also represent the majority of product innovation in the coming years, a lot of RWD is required. The global real-world evidence solutions market is estimated at 1.6 billion euros and assumed to grow to 4.1 billion euros by 2029, of which the European market represents about a quarter, and where Cascador pursues a leading position.
In their respective fields, Galenus and Neuroventis have gained the trust of specialised physicians and hospitals in Europe by demonstrating that their patient data platforms lead to well-founded and useful insights that contribute to improving patient well-being. The combination of hospital data registers now available to Cascador and the patient platform data from Galenus Health and Neuroventis offers unique insights into the progression of certain diseases.
Cascador aggregates data from patient apps, hospital systems, and other sources within these therapeutic areas using its robust, federated software platform. This platform ensures absolute security, governance, and compliance with legal requirements, while automatically converting the data into easily actionable insights. These data can then be safely and efficiently made available to the pharmaceutical sector, as well as academic research centres and hospitals.
“We are very excited about the expansion of Cascador through Galenus and Neuroventis. They strengthen our European presence alongside our existing projects in Belgium, France, and Switzerland, as well as expanding our operations to the UK and the US,” says CEO Philip Taillieu. He adds, “We are already discussing additional acquisitions. We are in the midst of an internationally consolidating market, and we plan on using that momentum.”
Jonathan Schreiber, co-founder of Neuroventis, adds: “By joining Cascador, we can accelerate our vision to improve the lives of neurology patients through data and digital technologies. Additionally, we can offer new data-related services to our clients.”
Gert Mariën, co-founder of Galenus Health, clarifies: “Combining the real-world data research capabilities in the field of immunology and respiratory of Galenus with the technology and capabilities to unlock real-world-data of Cascador, enables us to strengthen and jointly scale real-world-evidence solutions to life sciences organisations.”
Cascador Health is a Belgian scale-up that unlocks Real-World Data (RWD) for better health. It uses structured, validated, and anonymised RWD to generate Real-World Evidence, allowing healthcare providers and the life sciences industry to make informed decisions and provide better care. Founded in 2021 by experienced entrepreneurs and digital specialists and backed by VCs, Cascador Health is a unique player, combining the usability of data-based insights with complete compliance in a cost-efficient manner.
Galenus Health is a Belgian research and consultancy boutique in the immunology and respiratory space. Its CHRINOSOR program encompasses the European Outcome Registry for Chronic Rhinosinusitis based on both patient-reported and physician-reported data, and brings together a network of big pharma sponsors and physicians from top European clinical centres. Galenus Health delivers real-world evidence and insights related to mainly biological therapies through a series of multi-year studies and subsequent scientific publications.
Neuroventis is a Belgian-based CE-marked and FDA-registered digital care platform for neurology. Its technology enables people with neurological conditions and their healthcare providers to track and manage their health. Its platform is also used by research organizations worldwide, from academic institutions to leading pharma players (UCB, AbbVie), to advance science and bring new therapies to patients. Its apps Helpilepsy and MigraineManager support more than 20,000 epilepsy and headache patients and 500 healthcare professionals.
